Alfa Wassermann SpA
http://www.alfawassermann.com/en/alfa-wassermann
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alfa Wassermann SpA
Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products
Also deals involving WuXi/Medigene, Eisai/Seed, Genor/Two River/Third Rock Ventures, ImmuneOnco/Instil, Biocytogen/Ideaya, Takeda/Dr Reddy’s/Zydus/Mankind and deals in brief.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Pfizer bullish on its oral glp-1; BMS’s rising confidence about Medicare pricing of Eliquis; more long term data for Leqembi; NewAmsterdam’s CETP inhibitor shows promise; and a look at Mankind’s Bharat Serums buy.
Torrent On Acquisition And Licensing Strategy, Vonoprazan Trajectory
Amid deals activity in India, Torrent Pharma executives spelt out their acquisition expectations and licensing strategy while an in-licensed Takeda brand did well in Q1 of FY25. The US growth trajectory is seen determined by five to ten product approvals expected this fiscal.
$1.6bn Bharat Serums Buy Gives Mankind Dominance In Women's Health, R&D Engine
With an eye-catching $1.6bn deal, Mankind has acquired Bharat Serums and Vaccines to add a high-barrier, specialty business, a credible biologics R&D engine and a complementary portfolio of women’s fertility and health treatments while PE firm Advent finds a profitable exit. What’s next?
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Bama-Geve S.L., ALFASIGMA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice